Safety and tolerability of duloxetine – adverse events and how to handle them

Safety and tolerability of duloxetine – adverse events and how to handle them

Bibliographic Details
Main Author:	Haddad Peter
Format:	Article
Language:	English
Published:	BMC 2006-02-01
Series:	Annals of General Psychiatry
Online Access:	http://dx.doi.org/10.1186/1744-859X-5-S1-S22

Similar Items

A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine
by: Daniela Rodrigues-Amorim, et al.
Published: (2020-10-01)

Limits of functions – how do students handle them?
by: Kristina Juter
Published: (2005-10-01)

Duloxetine hydrochloride
by: Mohan Bhadbhade, et al.
Published: (2009-09-01)

Adverse drug reactions in elderly patients: how to predict them?
by: Wilson Jacob Filho, et al.
Published: (2007-09-01)

Study of the scale, nature and causes of adverse events and methods to identify them
by: Sari, Ali Baba-Akbari
Published: (2006)

Managing incompetent teachers: how do principals in Hong Kong handle them?.
Published: (1989)

Duloxetine induced hyponatremia
by: M Kulkarni
Published: (2015-01-01)

Efficacy and safety of duloxetine in osteoarthritis: a systematic review and meta-analysis
by: Mikala C. Osani, et al.
Published: (2019-09-01)

Duloxetine: A Review of its Safety and Efficacy in the Management of Fibromyalgia Syndrome
by: Howard S. Smith, et al.
Published: (2010-01-01)

Duloxetine: A Review of Its Safety and Efficacy in the Management of Fibromyalgia Syndrome
by: Howard S. Smith, et al.
Published: (2010-12-01)

Comparing the efficacy and safety of duloxetine and amitriptyline in the treatment of fibromyalgia: overview of systematic reviews
by: Áurea Dias de Farias, et al.
Published: (2020-07-01)

Is duloxetine an alternative in the treatment of osteoarthritis?
by: Joaquín Ananías, et al.
Published: (2017-10-01)

Duloxetine for the management of fibromyalgia syndrome
by: Beth A Scholz, et al.
Published: (2009-07-01)

Adverse Life Events: Do Home Care Clients Have Resources for Mastering Them?
by: Vjenka Garms-Homolová, et al.
Published: (2021-03-01)

Why are events important and how to compute them in geospatial research?
by: May Yuan
Published: (2020-12-01)

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
by: Harada E, et al.
Published: (2016-01-01)

The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-marketing adverse event reports
by: Perahia DG, et al.
Published: (2013-11-01)

Efficacy of duloxetine in achieving response and remission
by: Bauer Michael
Published: (2006-02-01)

A facile asymmetric synthesis of (S)-duloxetine
by: Kee-In Lee, et al.
Published: (2010-07-01)

The role of duloxetine in the treatment of anxiety disorders
by: Domenico De Berardis, et al.
Published: (2008-07-01)

Duloxetine in the treatment of generalized anxiety disorder
by: Alan Wright, et al.
Published: (2009-08-01)

Bleeding gums: Duloxetine may be the cause
by: Balhara YPS, et al.
Published: (2007-01-01)

Duloxetine in the management of chronic musculoskeletal pain
by: Smith EJ, et al.
Published: (2012-06-01)

Duloxetine in the treatment of generalized anxiety disorder
by: Trevor R Norman, et al.
Published: (2009-01-01)

Fungi in human pathology - are we ready to handle them?
by: Man Adrian
Published: (2018-10-01)

Efficacy and tolerability of short-term duloxetine treatment in adults with generalized anxiety disorder: A meta-analysis.
by: Xinyuan Li, et al.
Published: (2018-01-01)

Responding to adverse patient safety events in Viet Nam
by: Reema Harrison, et al.
Published: (2019-09-01)

An Exploration of Contributing Factors to Patient Safety and Adverse Events
by: Zadvinskis, Inga Mirdza
Published: (2015)

What are precedents and how should judges handle them? Considerations based on the jurisprudence of the European Court of Human Rights
by: Popović Dragoljub
Published: (2017-01-01)

Rewarding conversations -How to reach them, arrange them and spread them
by: Laberg, Åste
Published: (2010)

Duloxetine-induced hyponatraemia in a patient with hypocortisolaemia
by: Mayuko Ikeguchi, et al.
Published: (2020-01-01)

Duloxetine in panic disorder with somatic gastric pain
by: Preve M, et al.
Published: (2013-11-01)

Predictors of duloxetine adherence and persistence in patients with fibromyalgia
by: Cui Z, et al.
Published: (2012-06-01)

Update on duloxetine for the management of stress urinary incontinence
by: Maya Basu, et al.
Published: (2008-11-01)

Depression Treatment with Duloxetine and Reduction of Inability to Work
by: Michael Happich, et al.
Published: (2012-01-01)

Duloxetine in the management of diabetic peripheral neuropathic pain
by: Boomershine CS, et al.
Published: (2011-07-01)

Opsoclonus-myoclonus syndrome secondary to duloxetine toxicity
by: J. Trigo López, et al.
Published: (2021-04-01)

Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management
by: Jan Leipe, et al.
Published: (2019-06-01)

Patients’ experience of communication and handling of symptomatic adverse events in breast cancer patients receiving adjuvant chemotherapy
by: Christina Witt Bæksted, et al.
Published: (2019-11-01)

ERRORS AND ADVERSE EVENTS: THE INTERFACE WITH HEALTH PROFESSIONALS’ SAFETY CULTURE
by: Verusca Soares de Souza, et al.
Published: (2015-09-01)